



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

27 July 2022  
EMA/67996/2022  
Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 18-21 July 2022

During its July 2022 meeting, the CHMP reviewed 4 recommendations for eligibility to PRIME: 1 was granted and 3 were denied. In addition, 1 request was received but not started by EMA as it was deemed outside the scope of the scheme.

The individual outcomes adopted this month are listed below.

---

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands  
**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)  
**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union



## Eligibility granted

Name*	Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Glencicimab (ACT017)	Biological Medicinal Product	Haematology – Hemostaseology	Treatment of acute ischemic stroke	Nonclinical + Clinical exploratory	SME

\* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.




## Eligibility denied

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Chemical Medicinal Product	Neurology	Treatment of non-traumatic subarachnoid haemorrhage	Nonclinical + Clinical exploratory	SME
Chemical Medicinal Product	Oncology	Treatment of malignant glioma	Nonclinical + Clinical exploratory	SME
Chemical Medicinal Product	Oncology	First-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma in combination with PD-1 inhibitors	Nonclinical + Tolerability first in man	SME

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## Cumulative overview of PRIME eligibility recommendations adopted by 21 July 2022

■ Granted ■ Denied ■ Out of scope\* ■ Withdrawn



\* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.